Biogen has agreed to acquire private biotechnology company RayThera in a deal valued at up to $1 billion, strengthening the company’s growing focus on immunology and expanding its pipeline of potential treatments for immune-mediated diseases.
The transaction, announced by both companies, includes an upfront payment to RayThera shareholders as well as additional payments tied to the achievement of future clinical and regulatory milestones. The majority of the deal’s value is contingent on the successful advancement of RayThera’s pipeline through development and regulatory review.
The acquisition gives Biogen access to a portfolio of anti-inflammatory drug candidates that are being developed to address a variety of immune-related conditions. The companies believe the assets could provide opportunities to expand into new disease areas and support Biogen’s long-term growth strategy in immunology.
At the center of the acquisition is RayThera’s lead drug candidate, which is expected to enter Phase 1 clinical development in the third quarter of 2026. While specific details about the program have not been disclosed, the candidate is part of a broader portfolio designed to target inflammatory pathways involved in immune-mediated diseases.
Biogen has increasingly emphasized immunology as a key area of investment alongside its established presence in neurology. The acquisition reflects the company’s strategy of supplementing internal research efforts with external innovation and promising early-stage assets.
Priya Singhal, Executive Vice President and Head of Development at Biogen, said the acquisition will further strengthen the company’s immunology pipeline and create opportunities to pursue new therapeutic areas.
According to Singhal, the addition of RayThera’s assets has the potential to contribute meaningfully to Biogen’s long-term development portfolio. She added that the company is eager to advance the lead candidate into clinical testing and evaluate its potential across a range of immune-related conditions.
For RayThera, the deal represents a significant milestone in the company’s evolution from an early-stage research organization to a source of promising drug candidates for larger pharmaceutical companies. The company has focused on discovering and developing small-molecule therapies that can modulate immune responses and reduce harmful inflammation.
Qing Dong, co-founder, Chairman, and Chief Executive Officer of RayThera, said Biogen’s global expertise in immunology development made it the ideal partner to move the company’s programs forward.
Dong praised the efforts of RayThera’s scientific team, noting that the company had rapidly advanced an innovative pipeline of molecules that are now positioned for clinical development. He expressed confidence that Biogen’s resources and development capabilities would help maximize the potential of the programs.
Under the terms of the agreement, Biogen will assume responsibility for the future development, manufacturing, and worldwide commercialization of RayThera’s assets once the transaction closes. The deal remains subject to customary closing conditions, including regulatory approvals, and is expected to be completed during the third quarter of 2026.
The acquisition comes as pharmaceutical companies continue to pursue strategic deals to strengthen their pipelines and secure access to innovative therapies. For Biogen, the addition of RayThera’s anti-inflammatory programs provides another opportunity to diversify its research portfolio and establish a stronger presence in the rapidly growing immunology market.
If successfully developed, the acquired assets could potentially provide new treatment options for patients living with chronic immune-mediated diseases while helping Biogen build a broader and more sustainable pipeline for the future.